Figure 3.
Duration of response after fludarabine and rituximab in relation to CD69 expression. Progression free survival after treatment was significantly longer within CLL subgroup showing CD69 lower than 30% (60% vs. 40% at six years; P=0.010).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.